FDA Warns of Counterfeit Lumify Eye Drops Hitting the Market
Medically reviewed by Drugs.com.
By Physician’s Briefing Staff HealthDay Reporter
THURSDAY, Feb. 1, 2024 -- The U.S. Food and Drug Administration is sounding the alarm on counterfeit versions of Bausch & Lomb Lumify eye drops, an over-the-counter product approved for red eye relief.
The packaging for South Moon, Rebright, and FivFivGo eye drops mirrors the packaging for Lumify. However, samples of the knockoff South Moon eye drops were contaminated with Burkholderia cepacia complex, a strain of bacteria that could result in an antibiotic-resistant infection, the FDA said in a news release.
Rebright tested negative for contamination, but both Rebright and South Moon lacked the active ingredient in Lumify, brimonidine tartrate. No samples of FivFivGo drops could be obtained for testing and analysis.
The FDA recommends consumers not use any of the products, because they are unapproved and should not be for sale in the United States. Consumers who have bought these products should throw them out.
The origin of the products is currently unclear, the FDA added. The South Moon label says it is made by Shantou Cross-border Premium Products E-Commerce Co. Ltd. in China.
The FDA has not received any reports that specifically name South Moon, Rebright, or FivFivGo as a source of infection. However, the agency has received reports related to potentially fake Lumify, including product quality concerns, eye irritation, pain, and infection.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-02-02 06:15
Read more
- Work-Related Stress Linked to Lower Odds of Average, Optimal Heart Health
- Weed Use During Pregnancy May Harm Kids' Behavior, Thinking Skills
- FDA Approves Emrosi (minocycline hydrochloride) for the Treatment of Rosacea
- ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
- Toddler Diet Quality Improved Significantly From 1999 to 2018
- FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions